Statement

Le vaccin COVID-19 mis à jour de Novavax est désormais disponible en France

19 décembre 2023

La nouvelle formulation du vaccin Covid-19, Nuvaxovid® XBB.1.5 produit par Novavax est désormais disponible en France. Nuvaxovid® XBB.1.5 est vaccin à protéines recombinantes associé à l'adjuvant Matrix-M™. Il peut être utilisé pour la campagne vaccinale en cours.

Une dose unique de Nuvaxovid® XBB.1.5 est indiquée et recommandée pour la prévention de la Covid-19 chez les personnes âgées de 12 ans et plus qui souhaitent être vaccinés contre le Covid-19 quel que soit leur statut vaccinal, et qui ne souhaitent pas ou ne peuvent pas recevoir un vaccin à ARNm. Les rappels vaccinaux doivent toutefois être réalisés préférentiellement avec des vaccins à ARNm.

Dans l'attente de données complémentaires, l'utilisation du vaccin Nuvaxovid® n'est pas recommandée chez la femme enceinte. Le vaccin est disponible en pharmacie depuis le 14 décembre 2023. Il est distribué par le ministère de la Santé et est disponible à la commande sur le portail de Santé Publique France.

Forward-Looking Statements

Statements herein relating to the future of Novavax, its operating plans and prospects, including the availability of its updated XBB version of its Novavax COVID-19 Vaccine, Adjuvanted (2023-2024 Formula) (NVX-CoV2601) and the timing of delivery and distribution of its vaccine in France are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, challenges satisfying, alone or together with partners, various safety, efficacy, and product characterization requirements, including those related to process qualification and assay validation, necessary to satisfy applicable regulatory authorities; difficulty obtaining scarce raw materials and supplies; resource constraints, including human capital and manufacturing capacity, on the ability of Novavax to pursue planned regulatory pathways; challenges or delays in obtaining regulatory authorization for its product candidates, including its updated XBB version of its COVID-19 vaccine in time for the fall 2023 vaccination season or for future COVID-19 variant strain changes; challenges or delays in clinical trials; manufacturing, distribution or export delays or challenges; Novavax's exclusive

dependence on Serum Institute of India Pvt. Ltd. for co-formulation and filling and the impact of any delays or disruptions in their operations on the delivery of customer orders; challenges meeting contractual requirements under agreements with multiple commercial, governmental, and other entities; and those other risk factors identified in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Novavax's Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent Quarterly Reports on Form 10-Q, as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at www.sec.gov and www.novavax.com, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should consider these risks and uncertainties.

-END STATEMENT-